These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38791158)

  • 1. Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models.
    Revia S; Neumann F; Jabs J; Orio F; Sirrenberg C; Zimmermann A; Amendt C; Albers J
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
    Wise HC; Iyer GV; Moore K; Temkin SM; Gordon S; Aghajanian C; Grisham RN
    Sci Rep; 2019 Dec; 9(1):18882. PubMed ID: 31827119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA-Dependent Protein Kinase Inhibitor Peposertib Potentiates the Cytotoxicity of Topoisomerase II Inhibitors in Synovial Sarcoma Models.
    Revia S; Budzinska MA; Bogatyrova O; Neumann F; Zimmermann A; Amendt C; Albers J
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer.
    Wu YH; Hong CW; Wang YC; Huang WJ; Yeh YL; Wang BJ; Wang YJ; Chiu HW
    Cancer Lett; 2017 Aug; 400():79-88. PubMed ID: 28450160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cordycepin Enhances the Therapeutic Efficacy of Doxorubicin in Treating Triple-Negative Breast Cancer.
    Huang H; Li X; Wu W; Liu C; Shao Y; Wu X; Fu J
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center.
    Khallaf SM; Roshdy J; Ibrahim A
    J Egypt Natl Canc Inst; 2020 Apr; 32(1):20. PubMed ID: 32372114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
    Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
    Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
    Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
    PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
    Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
    J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.
    Guo Z; Luo J; Mashl RJ; Hoog J; Maiti P; Fettig N; Davies SR; Aft R; Held JM; Govindan R; Ding L; Li S; von Morze C; Wulf GM; Shoghi KI; Ma CX
    Cancer Res Commun; 2024 Jun; 4(6):1430-1440. PubMed ID: 38717161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
    Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
    Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
    Pattarawat P; Wallace S; Pfisterer B; Odoi A; Wang HR
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):141-152. PubMed ID: 31865420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
    Chittaranjan S; Bortnik S; Dragowska WH; Xu J; Abeysundara N; Leung A; Go NE; DeVorkin L; Weppler SA; Gelmon K; Yapp DT; Bally MB; Gorski SM
    Clin Cancer Res; 2014 Jun; 20(12):3159-73. PubMed ID: 24721646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining naringenin and metformin with doxorubicin enhances anticancer activity against triple-negative breast cancer in vitro and in vivo.
    Pateliya B; Burade V; Goswami S
    Eur J Pharmacol; 2021 Jan; 891():173725. PubMed ID: 33157041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
    Basho RK; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Herbrich SM; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Ibrahim NK; Murray JL; Koenig KB; Hong D; Subbiah V; Kurzrock R; Janku F; Moulder SL
    JAMA Oncol; 2017 Apr; 3(4):509-515. PubMed ID: 27893038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
    Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
    Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo.
    Lothstein L; Soberman J; Parke D; Gandhi J; Sweatman T; Seagroves T
    Oncol Res; 2020 Dec; 28(5):451-465. PubMed ID: 32430093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.